## Management and Prognosis of Acanthosis Nigricans **Key Point:** While topical agents may provide symptomatic improvement, they do NOT produce complete resolution of acanthosis nigricans. The lesions require treatment of the underlying cause. ### Management Approach by Etiology | Etiology | Primary Treatment | Prognosis | |----------|-------------------|----------| | **Metabolic (insulin resistance)** | Weight loss, glycemic control, metformin, thiazolidinediones | Slow improvement over months to years | | **Malignancy-associated** | Treatment of primary cancer | May regress with cancer remission | | **Endocrine (PCOS, acromegaly)** | Hormonal management | Variable, depends on underlying control | | **Drug-induced** | Discontinuation of offending agent | Gradual improvement | ### Topical Therapy—Limited Efficacy - **Agents used:** Retinoids (tretinoin, adapalene), keratolytics (salicylic acid, urea), vitamin D analogues - **Role:** Symptomatic improvement only (reduce pruritus, soften skin) - **Outcome:** Do NOT resolve the underlying pathology or produce complete clearance - **Why:** Topical agents cannot reverse the systemic insulin resistance or IGF signaling driving epidermal proliferation **High-Yield:** Topical therapy is adjunctive, NOT curative. Complete resolution requires addressing the metabolic or malignant cause. ### Indications for Systemic Investigation **Clinical Pearl:** In a lean, young patient with acanthosis nigricans (atypical presentation), screen for: - Occult malignancy (gastric, lung, breast, ovarian) - Endocrine disorders (PCOS, acromegaly, Cushing syndrome) - Genetic syndromes (HAIR-AN, Rabson-Mendenhall) **Warning:** Do NOT assume all acanthosis nigricans is metabolic. Atypical presentations demand systemic workup.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.